Skip to main content

Table 4 Mean (± SD) pharmacokinetic parameter estimates for oxaliplatin (day 2) using non-compartmental analysis

From: Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy

Oxaliplatin (mg/m 2 )

20/15 ( n  = 3)

20/22.5 ( n  = 3)

20/30 ( n  = 3)

25/30 ( n  = 3)

40/30 ( n  = 3)

50/30 ( n  = 22)

Visit

C1D2

C1D2

C1D2

C1D2

C1D2

C1D2

AUCall (h-ng/ml)

704.3 (228.5)

1,178.4 (238.0)

1,149.0 (930.3)

1,369.1 (556.1)

1,543.5 (502.1)

1,286.3 (627.0)

AUCinf (h-ng/ml)

1,003.5 (211.1)

1,359.3 (167.1)

1,411.6 (1,065.1)

1,919.4 (923.3)

1,867.0 (387.0)

1,455.9 (657.6)

C max (ng/ml)

337.3 (141.3)

573.5 (131.1)

446.9 (447.8)

582.6 (270.3)

751.7 (275.5)

649.4 (384.5)

t 1/2 (h)

38.9 (31.9)

17.9 (7.7)

18.6 (11.9)

23.7 (10.2)

23.3 (15.6)

16.5 (7.1)

CL (l/h/m2)

15.5 (3.7)

16.7 (2.0)

29.1 (15.7)

19.2 (11.4)

16.6 (3.9)

24.5 (10.2)

V d (l/m2)

829.2 (580.0)

443.5 (232.2)

794.5 (703.8)

587.5 (240.1)

613.8 (541.2)

554.0 (250.7)

  1. C max, maximum concentration; AUC, area under the curve; t 1/2, half-life of elimination; V d, volume of distribution; CL, clearance.